Systemic sclerosis, also known as scleroderma, is a rare and complex autoimmune
connective-tissue disease. Once considered an untreatable and unpredictable condition …

Fibrosis is defined as an excessive deposition of connective tissue components and can
affect virtually every organ system, including the skin, lungs, liver and kidney. Fibrotic tissue …

Background A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in
systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial …

Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ
involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous …

Objective Tocilizumab (TCZ) has demonstrated lung function preservation in 2 randomized
controlled trials in early systemic sclerosis (SSc). This effect has yet to be characterized in …

Systemic sclerosis (SSc; scleroderma) has the highest individual mortality of all rheumatic
diseases, and interstitial lung disease (ILD) is among the leading causes of SSc‐related …

Systemic sclerosis (scleroderma) is an autoimmune‐triggered chronic fibrosing disease that
affects the skin and many other organs. Its pathophysiology is complex and involves an early …

From the clinical standpoint, systemic sclerosis (SSc) is characterized by skin and internal
organ fibrosis, diffuse fibroproliferative vascular modifications, and autoimmunity. Clinical …

Systemic autoimmune rheumatic diseases (SARDs) exhibit extensive heterogeneity in
clinical presentation, disease course, and treatment response. Therefore, precision …

Janus kinase (JAK) inhibitors (also termed Jakinibs) constitute a family of small drugs that
target various isoforms of JAKs (JAK1, JAK2, JAK3 and/or tyrosine kinase 2 (Tyk2)). They …